1. Davydov MI, Aksel' EM. Statistika zlokachestvennykh novoobrazovanii v Rossii i stranakh SNG v 2013 godu. Vestnik RONTs im. N.N. Blokhina RAMN, 2015.
2. Perevodchikova NI, Stenina MB. Lekarstvennaya terapiya raka molochnoi zhelezy. M.: Praktika, 2014.
3. Stenina MB, Zhukova LG, Koroleva IA, Parokonnaya AA i soavt. Prakticheskie rekomendatsii po lekarstvennomu lecheniyu zlokachestvennykh opukholei. Invazivnyi rak molochnoi zhelezy. M., Zlokachestvennye opukholi. 2017;7(3):114-115.
4. Semiglazov VF, Paltuev RM, Semiglazov VV, Manikhas AG i soavt. Rannii rak molochnoi zhelezy: prognosticheskoe znachenie biologicheskikh podtipov (analiz kumulyativnoi bazy dannykh FGBU NII onkologii im. N.N. Petrova» Minzdravsotsrazvitiya. Zlokachestvennye opukholi. 2012;2(2):12-18.
5. Ferlay J, Soerjomataram I, Dikshit R, Eser S. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2014. International Journal of Cancer. 2014;136(5):E359-E386.
6. Gucalp A, Gupta G, Pilewskie M, Sutton E, Norton L. Advances in managing breast cancer: a clinical update. 2014/ F1000Prime Reports, 6.
7. Beaber E, Buist D, Barlow W, Malone K. Recent Oral Contraceptive Use by Formulation and Breast Cancer Risk among Women 20 to 49 Years of Age. Cancer Research. 2014;74(15):4078-4089.
8. Kennecke H, Yerushalmi R, Woods R, Cheang M, Voduc D, Speers C, Nielsen T, Gelmon K. Metastatic Behavior of Breast Cancer Subtypes. Journal of Clinical Oncology. 2010;28(20):3271-3277.
9. Senn H. St. Gallen Consensus 2013: Optimizing and Personalizing Primary Curative Therapy of Breast Cancer Worldwide. Breast Care. 2013;8(2):101-101.
10. Arvold N, Taghian A, Niemierko A, Abi Raad R. Age, Breast Cancer Subtype Approximation, and Local Recurrence After Breast-Conserving Therapy. Journal of Clinical Oncology. 2011;29(29):3885-3891.
11. Wu X, Baig A, Kasymjanova G, Kafi K, Holcroft C, Mekouar H, Carbonneau A, Bahoric B, Sultanem K, Muanza T Pattern of Local Recurrence and Distant Metastasis in Breast Cancer By Molecular Subtype. Cureus. 2016.
12. Tran B, Bedard P. Luminal-B breast cancer and novel therapeutic targets. Breast Cancer Research. 2011;13(6).
13. Chen S, Huang L, Chen C, Shao Z. Progesterone receptor loss identifies luminal-type local advanced breast cancer with poor survival in patients who fail to achieve a pathological complete response to neoadjuvant chemotherapy. Oncotarget. 2015;6(20).
14. Prat A, Cheang M, Martin M, Parker J. Prognostic Significance of Progesterone Receptor-Positive Tumor Cells Within Immunohistochemically Defined Luminal A Breast Cancer. Journal of Clinical Oncology. 2011;31(2):203-209.
15. Laurberg T, Alsner J, Tramm T, Jensen V, Lyngholm C. Impact of age, intrinsic subtype and local treatment on longterm local-regional recurrence and breast cancer mortality among low-risk breast cancer patients. Acta Oncologica. 2016;56(1):59-67.
16. Viale G, Regan M, Maiorano E, Mastropasqua MA. Prognostic and Predictive Value of Centrally Reviewed Expression of Estrogen and Progesterone Receptors in a Randomized Trial Comparing Letrozole and Tamoxifen Adjuvant Therapy for Postmenopausal Early Breast Cancer: BIG 1-98. Journal of Clinical Oncology. 2007;25(25):3846-3852.
17. Engel J, Eckel R, Aydemir Ü. Determinants and prognoses of locoregional and distant progression in breast cancer. International Journal of Radiation. International Journal of Radiation Oncology Biology Physics. 2003;55(5):1186-1195.
18. Albert J, Buchholz T. Basal subtype of invasive breast cancer is associated with a higher risk of true recurrence after conventional breast-conserving therapy. Breast Diseases: A Year Book Quarterly. 2012;23(3):288-289.
19. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673-1684.
20. Liedtke C, Mazouni C, Hess K, André F. Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer. Journal of Clinical Oncology. 2008;26(8):1275-1281.
21. Gangi A, Chung A, Mirocha J, Liou D. Breast-Conserving Therapy for Triple-Negative Breast Cancer. JAMA Surgery. 2014;149(3):252.
22. Abdulkarim B, Cuartero J, Hanson J, Deschênes J. Increased Risk of Locoregional Recurrence for Women With T1-2N0 Triple-Negative Breast Cancer Treated With Modified Radical Mastectomy Without Adjuvant Radiation Therapy Compared With Breast-Conserving Therapy. Journal of Clinical Oncology. 2011;29(21):2852-2858.
23. Adkins F, Gonzalez-Angulo A, Lei X, Hernandez-Aya L. Triple-Negative Breast Cancer Is Not a Contraindication for Breast Conservation. Annals of Surgical Oncology. 2011;18(11):3164-3173.
24. Zumsteg Z, Morrow M, Arnold B, Zheng J. Breast-Conserving Therapy Achieves Locoregional Outcomes Comparable to Mastectomy in Women with T1-2N0 Triple-Negative Breast Cancer. Annals of Surgical Oncology. 2013;20(11):3469-3476.
25. Yang T Morrow M, Modi S, Zhang Z. The Effect of Molecular Subtype and Residual Disease on Locoregional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Postmastectomy Radiation. Annals of Surgical Oncology. 2015;22(S3):495-501.
26. Wong F, Chua E. Hormone Receptors and HER-2 Status as Surrogates for Histological Subtypes Prognosticate for Disease Control in Node Negative Asian Breast Cancer Patients Treated with Breast Conservation Therapy. International Journal of Radiation Oncology Biology Physics. 2011;75(3):S183-S184.
27. Siponen E, Joensuu H, Vironen J, Heikkilä P. Ipsilateral breast recurrence after breast conserving surgery in patients with small (≤2 cm) breast cancer treated with modern adjuvant therapies Vaalavirta. European Journal of Surgical Oncology (EJSO). 2011;37(1):25-31.
28. Abdulkaraim H, Pinchinat T, Khan S, Landers A, Christos P, Simmons R, Moo T The impact of molecular subtype on breast cancer recurrence in young women treated with contemporary adjuvant therapy. The Breast Journal. 2017:S183-S184.
29. Braunstein L, Taghian A, Niemierko A, Salama L. Breast-cancer subtype, age, and lymph node status as predictors of local recurrence following breast-conserving therapy. Breast Cancer Research and Treatment. 2016;161(1):173-179.
30. Mannino M, Yarnold J. Local relapse rates are falling after breast conserving surgery and systemic therapy for early breast cancer: Can radiotherapy ever be safely withheld? Radiotherapy and Oncology. 2009;90(1):14-22.
31. Nguyen P, Taghian A, Katz M et al. Breast Cancer Subtype Approximated by Estrogen Receptor, Progesterone Receptor, and HER-2 Is Associated With Local and Distant Recurrence After Breast-Conserving Therapy. Journal of Clinical Oncology. 2009;26(14):2373-2378.
32. Lowery A, Kell M, Glynn R, Kerin M, Sweeney K. Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype. Breast Cancer Research and Treatment. Breast Cancer Research and Treatment. 2011;133(3):831-841.
33. Wang J, Xie X, Wang X, Tang J. Locoregional and distant recurrences after breast conserving therapy in patients with triple-negative breast cancer: A meta-analysis. Surgical Oncology. 2013;22(4):247-255.
34. Moran M. Radiation therapy in the locoregional treatment of triple-negative breast cancer. The Lancet Oncology. 2015;16(3):e113-e122.
35. King T, Radosa J, Eaton A, Stempel M, Khander A. Evaluation of Local and Distant Recurrence Patterns in Patients with Triple-Negative Breast Cancer According to Age. Annals of Surgical Oncology. 2016;24(3):698-704.
36. Gnant M., Harbeck N et al. St. Gallen/Vienna 2017: A Brief Summary of the Consensus Discussion about Escalation and De-Escalation of Primary Breast Cancer Treatment. Breast Care. 2017;12(2):102-107.
37. Chen Q., Wang X, Lin P, Zhang J. The different outcomes between breast-conserving surgery and mastectomy in tri ple-negative breast cancer: a population-based study from the SEER 18 database. Oncotarget. 2016;8(3).
38. Alabdulkareem H, Pinchinat T, Khan S, Landers A, Christos P, Simmons R, Moo T The impact of molecular subtype on breast cancer recurrence in young women treated with contemporary adjuvant therapy. The Breast Journal. 2017:S183-S184.